Corsair Pharma Announces $23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hypertension
September 20, 2023 08:00 ET
|
Corsair Pharma, Inc.
SUNNYVALE, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced the closing of its $23M...
Corsair Pharma, Inc. to Present at LifeSci Partners Annual Private Company Summer Symposium
July 15, 2021 08:00 ET
|
Corsair Pharma, Inc.
SOUTH SAN FRANCISCO, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced it will...
Corsair Pharma, Inc. to Host Key Opinion Leader Meeting on Pulmonary Arterial Hypertension
June 24, 2021 08:00 ET
|
Corsair Pharma, Inc.
SOUTH SAN FRANCISCO, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced it will host a...